Systematic Review and Meta-analysis of the Prevalence of Resistant Hypertension in Treated Hypertensive Populations
Overview
Authors
Affiliations
Background: Although treatment-resistant hypertension (RH) is a serious burden on population health, there exists uncertainty about its prevalence. Hence, the objectives of this work were to systematically review and critically appraise the literature and to conduct a meta-analysis on the prevalence of RH in treated hypertensive populations.
Methods: PubMed, Cochrane Library, CRD York databases, and study bibliographies were systematically searched for observational and interventional studies that report disease frequency in adult populations. The pooled prevalence was obtained through random-effect modeling. Furthermore, quality assessment, publication bias diagnostics, meta-regression, subgroup analysis by sex, and sensitivity analysis were performed.
Results: Out of 318 retrieved studies, 20 observational studies and 4 randomized control trials (RCTs) with a total population of 961,035 were included. The random-effect method for observational studies and RCTs yielded RH prevalence ratios of 13.72% (95% confidence interval (CI) = 11.19%-16.24%) and 16.32% (95% CI = 10.68%-21.95%), respectively. Yet, most studies were incapable of ruling out pseudo-resistance caused by white-coat effect, poor medication adherence, and suboptimal dosing. Differences in RH prevalence by sex were negligible. Meta-regression analysis showed that study-level characteristics had no statistically significant influence on RH prevalence. The inclusion of further studies in the sensitivity analysis concurred with the baseline results (13.19%; 95% CI = 10.89%-15.49%).
Conclusions: Researchers should enhance comparability of future empirical evidence through homogeneous methodologies and comparable baseline populations. This meta-analysis concludes that RH is a frequent phenomenon and further harmonization in terms of RH definition and measurement would be necessary to clearly distinguish true treatment resistance from pseudo-resistance.
Faconti L, George J, Partridge S, Maniero C, Sathyanarayanan A, Kulkarni S J Hum Hypertens. 2024; 39(1):1-14.
PMID: 39653728 PMC: 11717708. DOI: 10.1038/s41371-024-00983-6.
Lin S, Hsu Y, Kim J, Jackson J, Segal J J Gen Intern Med. 2024; .
PMID: 39358502 DOI: 10.1007/s11606-024-09068-z.
Jarade C, Zolotarova T, Moiz A, Eisenberg M EClinicalMedicine. 2024; 75:102789.
PMID: 39246720 PMC: 11377134. DOI: 10.1016/j.eclinm.2024.102789.
Pinheiro J, Bezerra M, Santos B, Resende-Neto A, Wichi R Int J Environ Res Public Health. 2024; 21(8).
PMID: 39200626 PMC: 11353715. DOI: 10.3390/ijerph21081015.
The Global Burden of Resistant Hypertension and Potential Treatment Options.
Buso G, Agabiti-Rosei C, Lemoli M, Corvini F, Muiesan M Eur Cardiol. 2024; 19:e07.
PMID: 38983582 PMC: 11231817. DOI: 10.15420/ecr.2023.51.